Drug Pipeline Quarterly Update: December 2020

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

December 2020 Quarterly Traditional Pipeline Update

December 2020 Quarterly Specialty Pipeline Update

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.

Related news

Perspectives

July 25, 2024

Quarterly Drug Pipeline: July 2024

Clinical insights and competitive intelligence on anticipated drugs in development

Perspectives

July 22, 2024

Oncology Insights: 2024 ASCO Annual Meeting key findings

Findings from this year’s American Society of Clinical Oncology (ASCO) Annual Meeting will likely lead to clinical practice changes and U.S. Food and Drug Administration (FDA) drug approvals or expansions

Perspectives

July 16, 2024

LISTEN NOW: Beyond the business – Stories of corporate kindness | Pharmacy Friends Podcast

In this episode, we talk about how our employees' help goes beyond our work in health care, aiding in philanthropic efforts

View all news